ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
December 06 2023 - 7:20AM
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for treatment of inflammatory and renal diseases, announces
publication of an article in the peer-reviewed journal, Diabetes,
demonstrating that AIM2 and NLRP3 inflammasome activation
contributes to development of atherosclerosis in two different
animal models of type 1 diabetes.
In the paper titled, “Hematopoietic NLRP3 and AIM2 inflammasomes
promote diabetes-accelerated atherosclerosis, but increased
necrosis is independent of pyroptosis,” the authors studied mouse
models of type 1 diabetes and atherosclerosis. Following are key
findings reported in the paper:
- Diabetic animals demonstrated activation of inflammasome
pathways, based on increased levels of plasma IL-1β and IL-18, and
elevated levels of cleaved caspase- 1 in the peritoneal cavity
fluid.
- Each of the two different type 1 diabetes models exhibited
similar levels of plasma IL- 1β and IL-18 and similar aortic lesion
sizes and severity.
- Diabetic mice deficient in NLRP3 and/or AIM2 had reduced aortic
lesion size compared to diabetic controls, indicating that NLRP3
and AIM2 inflammasome activation contributes to atherosclerotic
lesion development.
- Results are consistent with other animal model studies showing
deficiencies in essential inflammasome components, such as NLRP3,
AIM2, ASC, and caspase-1, appear to protect against
atherosclerosis.
To read the article, Click Here.
“The research published in Diabetes reinforces that inhibition
of multiple types of inflammasomes, not just NLRP3, may be required
to effectively control inflammation in diseases, such as
atherosclerosis, in which activation of more than one type of
inflammasome is pathogenic,” commented Stephen C. Glover, ZyVersa’s
Co-founder, Chairman, CEO and President. “ZyVersa’s Inflammasome
ASC inhibitor IC 100 is designed to inhibit formation of multiple
types of inflammasomes and their associated ASC specks to attenuate
initiation and perpetuation of damaging inflammation contributing
to numerous diseases.” To review a white paper summarizing the
mechanism of action and preclinical data for IC 100, Click
Here.
About Inflammasome ASC Inhibitor IC 100
IC 100 is a novel humanized IgG4 monoclonal antibody that
inhibits the inflammasome adaptor protein ASC. IC 100 was designed
to attenuate both initiation and perpetuation of the inflammatory
response. It does so by binding to a specific region of the ASC
component of multiple types of inflammasomes, including NLRP1,
NLRP2, NLRP3, NLRC4, AIM2, Pyrin. Intracellularly, IC 100 binds to
ASC monomers, inhibiting inflammasome formation, thereby blocking
activation of IL-1β early in the inflammatory cascade. IC 100 also
binds to ASC Specks, both intracellularly and extracellularly,
further blocking activation of IL-1β and the perpetuation of the
inflammatory response that is pathogenic in inflammatory diseases.
Because active cytokines amplify adaptive immunity through various
mechanisms, IC 100, by attenuating cytokine activation, also
attenuates the adaptive immune response.
About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty
biopharmaceutical company leveraging advanced, proprietary
technologies to develop first-in-class drugs for patients with
renal and inflammatory diseases who have significant unmet medical
needs. The Company is currently advancing a therapeutic development
pipeline with multiple programs built around its two proprietary
technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment
of kidney diseases, and Inflammasome ASC Inhibitor IC 100,
targeting damaging inflammation associated with numerous CNS and
other inflammatory diseases. For more information, please visit
www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
Corporate and IR Contact:Karen CashmereChief
Commercial
Officerkcashmere@zyversa.com786-251-9641
Media ContactsTiberend Strategic Advisors,
Inc.Casey McDonaldcmcdonald@tiberend.com646-577-8520
Dave Schemeliadschemelia@tiberend.com609-468-9325
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Apr 2024 to May 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From May 2023 to May 2024